Cognitive Impairment Associated with Schizophrenia Market Forecast 2015

1
Cognitive Impairment Associated With
Schizophrenia (CIAS)Pipeline Review, H2 2015
No. Pages 110
Published on October - 2015
2
.
Report Overview
About Cognitive Impairment Associated with
Schizophrenia (CIAS)Pipeline Review, H2
2015 Research Beam added report on Cognitive
Impairment Associated with Schizophrenia
(CIAS)Pipeline Review, H2 2015. Summary Global
Markets Directs, Cognitive Impairment Associated
with Schizophrenia (CIAS)Pipeline Review, H2
2015, provides an overview of the Cognitive
Impairment Associated With Schizophrenia (CIAS)s
therapeutic pipeline. This report provides
comprehensive information on the therapeutic
development for Cognitive Impairment Associated
with Schizophrenia (CIAS), complete with
comparative analysis at various stages,
therapeutics assessment by drug target, mechanism
of action (MoA), route of administration (RoA)
and molecule type, along with latest updates, and
featured news and press releases. It also reviews
key players involved in the therapeutic
development for Cognitive Impairment Associated
with Schizophrenia (CIAS) and special features on
late-stage and discontinued projects. Get Full
Details On http//www.researchbeam.com/cognitive
-impairment-associated-with-schizophrenia-cias-pip
eline-review-h2-2015-market
3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.  
4
.
Report Overview
Scope The report provides a snapshot of the
global therapeutic landscape of Cognitive
Impairment Associated With Schizophrenia
(CIAS) The report reviews key pipeline products
under drug profile section which includes,
product description, MoA and RD brief, licensing
and collaboration details other developmental
activities The report reviews key players
involved in the therapeutics development for
Cognitive Impairment Associated With
Schizophrenia (CIAS) and enlists all their major
and minor projects The report summarizes all the
dormant and discontinued pipeline projects A
review of the Cognitive Impairment Associated
With Schizophrenia (CIAS) products under
development by companies and universities/research
institutes based on information derived from
company and industry-specific sources Pipeline
products coverage based on various stages of
development ranging from pre-registration till
discovery and undisclosed stages A detailed
assessment of monotherapy and combination therapy
pipeline projects
5
Report Overview
Coverage of the Cognitive Impairment Associated
With Schizophrenia (CIAS) pipeline on the basis
of   target, MoA, route of administration and
molecule type Latest news and deals relating
related to pipeline products Reasons to
buy  Provides strategically significant
competitor information, analysis, and insights to
formulate effective RD development
strategies Identify emerging players with
potentially strong product portfolio and create
effective counter-strategies to gain competitive
advantage Develop strategic initiatives by
understanding the focus areas of leading
companies Identify and understand important and
diverse types of therapeutics under development
for Cognitive Impairment Associated With
Schizophrenia (CIAS) Plan mergers and
acquisitions effectively by identifying key
players of the most promising pipeline Devise
corrective measures for pipeline projects by
understanding Cognitive Impairment Associated
With Schizophrenia (CIAS) pipeline depth and
focus of Indication therapeutics. etc.  
6
Table Of Contents
List of Tables 7List of Figures 8Introduction
9Global Markets Direct Report Coverage
9Cognitive Impairment Associated With
Schizophrenia (CIAS) Overview 10Therapeutics
Development 11Pipeline Products for Cognitive
Impairment Associated With Schizophrenia (CIAS) -
Overview 11Pipeline Products for Cognitive
Impairment Associated With Schizophrenia (CIAS) -
Comparative Analysis 12Cognitive Impairment
Associated With Schizophrenia (CIAS) -
Therapeutics under Development by Companies
13Cognitive Impairment Associated With
Schizophrenia (CIAS) - Pipeline Products Glance
15Late Stage Products 15Clinical Stage Products
16
7
Table Of Contents
Atrial Fibrillation - Products under Development
by Companies 18Atrial Fibrillation - Products
under Investigation by Universities/Institutes
20Atrial Fibrillation - Companies Involved in
Therapeutics Development 21ARCA biopharma, Inc.
21Armetheon, Inc. 22 AstraZeneca Plc
23Bristol-Myers Squibb Company 24Cardiome
Pharma Corp. 25Daiichi Sankyo Company, Limited
26Gilead Sciences, Inc. 27Isis Pharmaceuticals,
Inc. 28Laboratoires Pierre Fabre SA 29Nissan
Chemical Industries, Ltd. 30Nyken BV 31
8
Table Of Contents
Early Stage Products 17Cognitive Impairment
Associated With Schizophrenia (CIAS) - Products
under Development by Companies 18Cognitive
Impairment Associated With Schizophrenia (CIAS) -
Companies Involved in Therapeutics Development
20AbbVie Inc. 20Amarantus Bioscience Holdings,
Inc. 21Astellas Pharma Inc. 22Avineuro
Pharmaceuticals, Inc. 23Bristol-Myers Squibb
Company 24Eli Lilly and Company 25Enquiry about
this report _at_ http//www.researchbeam.com/cognitiv
e-impairment-associated-with-schizophrenia-cias-pi
peline-review-h2-2015-market/enquire-about-report

9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/cognitive-impairment-a
ssociated-with-schizophrenia-cias-pipeline-review-
h2-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com